To Assess the Antiviral Activity of Pioglitazone and Prednisone in Obese Subjects With HCV Genotype 1 or 4 Infection, Insulin Resistance and Liver Inflammation Related to Non-alcoholic Fatty Liver.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Pioglitazone; Prednisone
- Indications Hepatitis C; Insulin resistance
- Focus Pharmacodynamics
- 02 Dec 2019 Biomarkers information updated
- 11 Feb 2013 Planned end date changed from 1 Sep 2012 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 23 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.